

Message from the President



We spend a lot of time each day communicating with our customers—veterinarians and animal owner/guardians. These conversations are very important to us and we

endeavor to respond quickly to customer inquiries, particularly those involving product-related technical questions.

We track these communications in order to ensure the appropriate follow-up has been completed.

Occasionally, we are contacted about an adverse event related to one of our products. This can be a mild side effect or, very rarely, a serious one. Serious adverse events are thoroughly investigated to determine what role, if any, our product played in the outcome. A regulatory

form is promptly filled out and uploaded through a portal for our primary regulator—the U.S. Department of Agriculture—to review.

Needless to say, we are always concerned when an adverse event is reported to us, and we are hopeful that the treated animal did not suffer harm.

Luckily, serious adverse events related to our products have been rare. We aim to keep it that way to the best of our ability.

Equimune[®] immunotherapy for equine respiratory disease

Equimune[®] is our standalone antiviral treatment that jump-starts the immune system to help resolve Equine Respiratory Disease Complex (ERDC).

It is regulator-approved in the USA, Australia and New Zealand for intravenous administration. It will stimulate both innate and specific immune responses, as needed, for several days.

In the early stages of a viral infection, Equimune:

- ◆ reduces the time available for viral replication
- ◆ reduces the number of tissue cells affected
- ◆ reduces the degree of cellular damage
- ◆ reduces the duration of clinical signs and physiological abnormalities

What you may not know about Equimune is that it can be used alongside vaccines.

Equimune has been tested in conjunction with a commercial West Nile virus (WNV) vaccine in horses.



WNV is a mosquito-borne virus that causes inflammation of the brain and spinal cord of horses, producing neurological symptoms.

In the 50-horse (unpublished) study, Equimune was administered alongside the vaccine. A full dose of Equimune triggered more animals to seroconvert (generate antibodies in the blood) and

triggered earlier seroconversion among the horses in the study.

Equimune has also been used to treat foals who had chronic *Streptococcus zooepidemicus* infection. Half a mature horse dose per foal every two weeks for 12 weeks resolved the problem for Hilldale Farm in Texas. The farm now uses Equimune routinely to keep its foals healthy.



Employee profile: Cassandra McRae

We often reference our valued employees, but we don't often talk about them in detail. We're pleased to introduce this feature in our quarterly newsletter focused on our hardworking employees. In this edition, we learn more about Cassandra McRae, Director of Operations for NovaVive.

Q: How long have you worked with NovaVive?

CM: I started in January, 2017.

Q: What did you do before joining NovaVive?

CM: I worked as project coordinator for Bioniche Therapeutics, then Telesta Therapeutics.

Q: What is your background/education?

CM: I have a BA in English Literature from Concordia University in Montreal, Quebec, Canada.



What do you like most about your job?

CM: There are always different challenges as we are a small company, so work never becomes monotonous.

Q: What makes you most proud about your work?

CM: I love hearing feedback from pet guardians and knowing we have helped someone's beloved pet.

Q: If you were to have done something else, career-wise, what would it have been?

CM: I would have loved to have opened a book store.

Q: What is your favourite hobby in your down time?

CM: Puzzles! I love staying up late on the weekends and working on puzzles. Birdwatching - since I've moved to the forest, I've enjoyed the hummingbirds. Hanging out with Ted, my rescued American Bully mix.

Q: What is something surprising that most people don't know about you?

CM: I currently have about 200 houseplants ... and growing.

Immunocidin[®] feedback from pet guardians


Cancer is the leading cause of death in senior dogs in North America. The Animal Cancer Foundation in the U.S. estimates that approximately 6 million dogs are diagnosed with cancer in the U.S. alone each year. About 40% of these will die from the disease each year.

Immunocidin[®] is our regulator-approved anticancer immunotherapy for the treatment of canine mammary tumors and mammary adenocarcinoma. It is approved and available in the U.S. and Canada.

NovaVive has an ongoing program exploring other cancers for which Immunocidin may be effective. Veterinarians who are interested in exploring Immunocidin as a treatment option are in regular contact with the NovaVive technical team to consider the best approaches. Each case is unique and responds differently to therapy.

Pet Guardians whose pets have experienced Immunocidin treatment often tell us what a difference it has made in their dog or cat's life. Some animals experience an

extended survival time with Immunocidin as part of their treatment plan. Others seem to have better quality of life in their last days.



Bama Belle was a 12-year-old Havanese from Alabama who had hemangiosarcoma in the heart. She passed away on June 26th, almost 39 weeks after starting Immunocidin therapy.

"I am so proud of my girl for making it as long as she did.

In spite of her discomfort and, most likely, more pain than she ever revealed, she was never fussy nor difficult in any way. She was a champion throughout it all. Truly ... she was my angel here on earth. Thank you for your generosity, your compassion, and your willingness to help give my girl a chance to fight this evil disease. I believe we were blessed with more time because of you and Immunocidin. I am eternally grateful for everything you provided during this difficult period."

Dolly is an 11-year-old retired racing greyhound living with her family in Columbus, Ohio. She was diagnosed with osteosarcoma in August, 2021. She underwent amputation and chemotherapy treatment and has been on Immunocidin therapy for 199 weeks (last update September 5, 2025).



"Dolly is doing wonderfully! She has just passed the 4-year anniversary of her diagnosis and continues to thrive. She loves snacks, hanging out in the backyard, and receiving lots of attention! She recently celebrated her 11th birthday, and we are so blessed to watch her age gracefully and enjoy life!"